PH22481A - N,n-dimethyl-1-/-(4-chlorophenyl) cyclobutyl/-3-methylbuttlamine hydrochloride monhydrate, composition thereof and method of use - Google Patents

N,n-dimethyl-1-/-(4-chlorophenyl) cyclobutyl/-3-methylbuttlamine hydrochloride monhydrate, composition thereof and method of use

Info

Publication number
PH22481A
PH22481A PH34552A PH34552A PH22481A PH 22481 A PH22481 A PH 22481A PH 34552 A PH34552 A PH 34552A PH 34552 A PH34552 A PH 34552A PH 22481 A PH22481 A PH 22481A
Authority
PH
Philippines
Prior art keywords
cyclobutyl
chlorophenyl
dimethyl
methylbuttlamine
monhydrate
Prior art date
Application number
PH34552A
Other languages
English (en)
Inventor
Jeffery James Edward
Whybrow Derek
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10589895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH22481(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of PH22481A publication Critical patent/PH22481A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PH34552A 1985-12-17 1986-12-04 N,n-dimethyl-1-/-(4-chlorophenyl) cyclobutyl/-3-methylbuttlamine hydrochloride monhydrate, composition thereof and method of use PH22481A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Publications (1)

Publication Number Publication Date
PH22481A true PH22481A (en) 1988-09-12

Family

ID=10589895

Family Applications (1)

Application Number Title Priority Date Filing Date
PH34552A PH22481A (en) 1985-12-17 1986-12-04 N,n-dimethyl-1-/-(4-chlorophenyl) cyclobutyl/-3-methylbuttlamine hydrochloride monhydrate, composition thereof and method of use

Country Status (34)

Country Link
US (2) US4929629A (de)
EP (1) EP0230742B1 (de)
JP (1) JPS62155240A (de)
KR (1) KR940008913B1 (de)
CN (1) CN1016245B (de)
AT (1) ATE56942T1 (de)
AU (1) AU601167B2 (de)
CA (1) CA1266278A (de)
CS (1) CS259545B2 (de)
DD (1) DD263050A5 (de)
DE (1) DE3674570D1 (de)
DK (1) DK170770B1 (de)
EG (1) EG17770A (de)
ES (1) ES2018163T4 (de)
FI (1) FI90413C (de)
GB (1) GB8531071D0 (de)
GE (1) GEP19970812B (de)
GR (1) GR3001069T3 (de)
HU (1) HU201901B (de)
IE (1) IE59429B1 (de)
IL (1) IL80934A (de)
IN (1) IN163129B (de)
LU (1) LU90865I2 (de)
MX (1) MX4684A (de)
NL (1) NL300065I1 (de)
NO (2) NO165540C (de)
NZ (1) NZ218578A (de)
PH (1) PH22481A (de)
PL (1) PL149519B1 (de)
PT (1) PT83958B (de)
SU (1) SU1443796A3 (de)
UA (1) UA7206A1 (de)
YU (1) YU46033B (de)
ZA (1) ZA869078B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
WO1994000047A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
WO1994000114A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE4443891A1 (de) 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
KR20010111254A (ko) * 1999-01-20 2001-12-17 토마스 와이. 올맨 금연 보조 방법
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
IL145244A (en) 1999-03-19 2006-12-10 Abbott Gmbh & Co Kg A method of treating apnea during sleep
US6376553B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Treatment of pain
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
AU3757200A (en) 1999-03-19 2000-10-09 Knoll Gmbh Treatment of pulmonary hypertension
AU3760600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
WO2000056310A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
US6441046B1 (en) 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
JP2002539255A (ja) * 1999-03-19 2002-11-19 クノール・ゲー・エム・ベー・ハー 体重増加に関係する癌の治療
AU3894600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating sexual dysfunction
WO2000056308A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
TR200102699T2 (tr) * 1999-03-19 2002-03-21 Knoll Gmbh Kronik mafsal bozukluĞunun (osteoarthritis) tedavisi
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
PE20011065A1 (es) 2000-02-01 2001-11-21 Procter & Gamble Proceso para fabricar bisfosfonatos geminales
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
US6610887B2 (en) * 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
JP3813152B2 (ja) * 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
BR0315084A (pt) * 2002-10-05 2005-08-16 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
KR20070084455A (ko) * 2004-11-23 2007-08-24 워너-램버트 캄파니 엘엘씨 지질혈증 치료용 ｈｍｇ ｃｏ-ａ 환원효소 억제제로서의7-(2ｈ-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
CN101098850B (zh) 2005-01-06 2010-09-15 Cj第一制糖株式会社 西布曲明的无机酸盐
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
WO2007015162A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
WO2007034910A1 (ja) * 2005-09-22 2007-03-29 Eisai R & D Management Co., Ltd. 過食症及び過食症に伴ううつ病の治療用医薬組成物
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007096763A2 (en) * 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
RU2462451C2 (ru) * 2006-09-15 2012-09-27 Ривайва Фармасьютикалс, Инк. Способ получения, способы применения и композиции циклоалкилметиламинов
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
WO2008059335A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
WO2008062276A2 (en) * 2006-11-20 2008-05-29 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
CA2681449A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
CN102171206B (zh) * 2008-08-06 2014-06-25 辉瑞股份有限公司 作为mc4激动剂的二氮杂环庚烷和二氮杂环辛烷
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
DK2496583T3 (en) 2009-11-02 2015-02-02 Pfizer Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
EA201291384A1 (ru) 2010-07-06 2013-07-30 Астразенека Аб Терапевтические агенты 976
KR101890959B1 (ko) 2010-11-08 2018-08-22 알비레오 에이비 간질환 치료를 위한 ｉｂａｔ 억제제
BR112013010705B1 (pt) 2010-11-08 2020-11-17 Albireo Ab uso de um inibidor de ibat e um coagulante de ácido biliar, e formulação farmacêutica
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
CN110372522B (zh) * 2019-07-30 2020-10-02 南京工业大学 一种从含有戊二胺的固相中汽提回收戊二胺的方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
LU90865I2 (fr) 2002-02-18
PT83958B (pt) 1989-05-12
DE3674570D1 (de) 1990-10-31
NO2005022I1 (no) 2005-10-03
SU1443796A3 (ru) 1988-12-07
FI865030A (fi) 1987-06-18
IE59429B1 (en) 1994-02-23
HUT45964A (en) 1988-09-28
US5068440A (en) 1991-11-26
FI90413C (fi) 1994-02-10
IL80934A (en) 1990-07-26
NO865093L (no) 1987-06-18
HU201901B (en) 1991-01-28
DD263050A5 (de) 1988-12-21
ES2018163T4 (es) 2012-06-14
AU6644286A (en) 1987-06-18
YU46033B (sh) 1992-12-21
CN1016245B (zh) 1992-04-15
CA1266278A (en) 1990-02-27
FI865030A0 (fi) 1986-12-10
PT83958A (en) 1987-01-01
UA7206A1 (uk) 1995-06-30
DK585786A (da) 1987-06-18
GR3001069T3 (en) 1992-03-20
PL149519B1 (en) 1990-02-28
GEP19970812B (en) 1997-02-10
JPH0144176B2 (de) 1989-09-26
AU601167B2 (en) 1990-09-06
FI90413B (fi) 1993-10-29
CS930586A2 (en) 1988-02-15
CN86108547A (zh) 1987-08-19
IN163129B (de) 1988-08-13
ES2018163B3 (es) 1991-04-01
GB8531071D0 (en) 1986-01-29
ATE56942T1 (de) 1990-10-15
CS259545B2 (en) 1988-10-14
JPS62155240A (ja) 1987-07-10
NO165540C (no) 1991-02-27
MX4684A (es) 1993-12-01
EP0230742A1 (de) 1987-08-05
PL263020A1 (en) 1988-05-12
EP0230742B1 (de) 1990-09-26
KR940008913B1 (ko) 1994-09-28
US4929629A (en) 1990-05-29
NZ218578A (en) 1989-04-26
KR870005961A (ko) 1987-07-08
ZA869078B (en) 1987-07-29
IE863102L (en) 1987-06-17
NO165540B (no) 1990-11-19
YU205086A (en) 1987-12-31
EG17770A (en) 1991-03-30
DK170770B1 (da) 1996-01-15
DK585786D0 (da) 1986-12-05
NL300065I1 (nl) 2001-12-01
NO865093D0 (no) 1986-12-16

Similar Documents

Publication Publication Date Title
PH22481A (en) N,n-dimethyl-1-/-(4-chlorophenyl) cyclobutyl/-3-methylbuttlamine hydrochloride monhydrate, composition thereof and method of use
CA2003524A1 (en) Treatment of obesity
NZ212067A (en) Derivatives of glycerophosphocholine and glycerophosphoethanolamine; preparation and use
ES542430A0 (es) Un procedimiento para la preparacion de una composicion antiacida de alginato de magnesio.
NZ230356A (en) 2',3'-dideoxy-5-ethynyl-3'-fluorouridine: preparatory processes and pharmaceutical compositions
GB2184122B (en) N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GR3001862T3 (en) Pharmaceutical preparation for tinea pedis
ES8702142A1 (es) Procedimiento para preparar un medicamento a base de 2-amino-3-carboetoxiamino-6-(4-fluoro-bencilamino)-piridina y 4-acetamido-fenol
IT8468196A1 (it) Dispositivo osmotico e procedimento per l'erogazione di un agente benefico, particolarmente di un farmaco ad un ambiente d'uso.
IL71176A (en) Analgesic preparation containing tizanidine and paracetamol
GB2135884B (en) Analgesic preparations containing tizanidine and paracetamol
HUT41817A (en) Process for preparing p-/acyl-amino/-benzamides
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
PH24690A (en) 8 alpha(-acylaminoergoline, pharmaceutical composition containing said compound and method of use thereof
DK162086A (da) Laegemiddel indeholdende vaevs-plasminogenaktivator, dets fremstilling og anvendelse
DK222988A (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
IL103313A (en) Pharmaceutical compositions comprising a tramadol material and acetaminophen